# Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC

> **NCT00173862** · PHASE2 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 18 (actual)

## Conditions studied

- Transitional Cell Carcinoma

## Interventions

- **DRUG:** Gemcitabine, Ifosfamide

## Key facts

- **NCT ID:** NCT00173862
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2007-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00173862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00173862, "Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00173862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*